Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review

Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review

Clinical trials for oncology drug development have long relied on surrogate outcome biomarkers that assess changes in tumor burden to accelerate drug registration (i.e., Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria). Drug-induced reduction in tumor size represents...

Full description

Bibliographic Details
Main Authors: Ionut-Gabriel Funingana, Pubudu Piyatissa, Marika Reinius, Cathal McCague, Bristi Basu, Evis Sala
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
imaging biomarkers
clinical trials
surrogate endpoints
volumetric
radiomics
data integration
Online Access:https://www.mdpi.com/2072-6694/14/20/5076

Similar Items

Similar Items